Aviation Committee completes probe into Falcon jet crash in Moscow’s Vnukovo airportWorld October 25, 15:04
Turkey, Russia exchange intelligence information on Syria — ministerWorld October 25, 14:38
Kremlin comments on hacker allegations against Putin's aide SurkovRussian Politics & Diplomacy October 25, 14:17
Diplomat says US likely to continue hostile policy towards Russia under new presidentRussian Politics & Diplomacy October 25, 13:58
IOC forwards Russia set of questions on doping control in 2010-2015Sport October 25, 13:48
Russian Strategic Missile Force successfully test-fires RS-18 ICBM at Kamchatka rangeMilitary & Defense October 25, 13:41
Russian diplomat points to difficulties hampering Lausanne-format talksRussian Politics & Diplomacy October 25, 13:33
US presidential campaign does no credit to American colleagues — LavrovRussian Politics & Diplomacy October 25, 13:11
Kremlin wants Western media's unbiased coverage of Russian, Syrian troops' activitiesRussian Politics & Diplomacy October 25, 13:07
NOVOSIBIRSK, November 14 (Itar-Tass) - Scientists at Russia's SibEnzyme enterprise in the Siberian city of Novosibirsk have developed a brand new method to diagnose oncological diseases at very early stages, the company’s chief executive, Yevgeny Dubinin, told Itar-Tass at the international forum for technological development Technoprom.
The new method allows to detect cancer cells even if the sample under scrutiny (blood, phlegm, urine or smear) contains only few DNA molecules with abnormally methylated (abnormally working, ‘silent’ genes), according to Dubinin.
The company’s enzyme, whose patented technology detects methylated genes, is used as a tumor marker. Analysis is simple and reliable - carried out on standard equipment, in one vial and in three stages, it takes only about four hours.
“There is almost no early cancer diagnostic in Russia, while treating the disease when it is detected at the third and fourth stages yields little effect,” Dubinin said.
The new method will be indispensable for oncological centres, diagnostic laboratories, and other medical institutions, the director added. The estimated market volume is about 5.5 million examinations and 1.8 million for rare types of cancer.